CAPA serves as the engine of a high-performance Pharmaceutical Quality System (PQS). It shifts quality management from reactive "firefighting" to a results-oriented strategy that optimizes processes across manufacturing and the global supply chain. Authorities such as the FDA, WHO, EMA, and CDSCO require a robust CAPA system. During GMP inspections, your CAPA records tell the story of your quality culture and your commitment to operational excellence.

This June 2026 notification signals a maturing pharmacovigilance framework. For stakeholders from large-scale manufacturers and CMOs to frontline healthcare providers, the message is clear: scientific justification is the only path to market survival. This article breaks down the ban and explores the strategic shifts necessary for industry compliance.